1. Background {#sec10899}
=============

There has been a rapid increase in the use of medical technologies in the recent years. It is clear that proper use of these technologies can significantly improve the patients' conditions; however, uncontrolled and inappropriate use of them might lead to a waste of limited resources ([@A8559R1]). PET scan is a non-invasive, expensive medical imaging technology that was introduced in 1950. This technology is currently used for diagnosis and treatment of various diseases, especially cancers across the world ([@A8559R2]). Compared to the MRI and CT scan that explore the cancer lesions at an anatomical level, this technology can explore the cancer lesions at cellular and biochemical levels that might lead to a higher diagnostic performance ([@A8559R3]). Various countries have commonly used PET scan for staging and treatment of cancers, especially lung cancers and non small cell lung carcinoma (NSCLC). Approximately 85% to 90% of lung cancers are non-small cell lung carcinoma (NSCLC) ([@A8559R2]). Recent studies from the UK and Australia have shown that the technology is significantly cost-effective, particularly when it is used for staging and treatment of NSCLC and lymphoma ([@A8559R3], [@A8559R5]). It is argued that the evidence regarding the technical performance and effectiveness of technologies are generalizable between the countries, but the cost-effectiveness evidence cannot be generalized to other countries ([@A8559R6]).

2. Objectives {#sec10900}
=============

The main purpose of this research is to explore the cost effectiveness of PET scan in staging and treatment of NSCLC in Iran that might then help optimize the allocation of limited resources.

3. Materials and Methods {#sec10901}
========================

The process of using PET scan in staging lung cancer: PET scan is not normally used for screening and diagnosis of lung cancer. When a patient is diagnosed with lung cancer and the biopsy shows that the cancer is NSCLC, then normally a CT scan is performed to explore any metastasis ([@A8559R3]). The accuracy of CT scan for detecting the cancer metastasis is moderate and performing a PET scan at this stage can improve the accuracy of staging ([@A8559R3]). The accuracy of PET scan at this stage is different depending on the result of the CT scan, whether it is positive or negative. In addition, according to the marker studies ([@A8559R3], [@A8559R5]), there are seven possible strategies for detecting metastasis in NSCLC after CT scan. Therefore, for the purpose of economic evaluation, we designed a standard decision tree model that included seven strategies after the CT scan was negative and seven strategies after the CT scan was positive consisting of a total of 14 strategies ([Table 1](#tbl3368){ref-type="table"}).

###### Seven Major Strategies Used in the Modeling of Cost Effectiveness

  Strategy                                                                                  Explanation
  ----------------------------------------------------------------------------------------- -------------------------------------------------
  1                                                                                         Sending all patients for surgery
  2                                                                                         Sending all patients for non-surgical treatment
  3                                                                                         All patients were examined by mediastinoscopy
  a\. If mediastinoscopy is negative, surgery will be done                                  
  b\. If mediastinoscopy is positive, non-surgical treatment will be done                   
  4                                                                                         All patients were examined by mediastinoscopy
  a\. If mediastinoscopy is negative, PET scan will be done                                 
  1\) If FDG-PET is negative, surgery will be done                                          
  2\) If FDG-PET is positive, non-surgical treatment will be done                           
  b\. If mediastinoscopy is positive, nonsurgical treatment will be done                    
  5                                                                                         All patients were examined by FDG-PET
  a\. If FDG-PET is negative, surgery will be done                                          
  b\. If FDG-PET is positive, non-surgical treatment will be done                           
  6                                                                                         All patients were examined by FDG-PET
  a\. If FDG-PET is negative, mediastinoscopy will be done                                  
  1)If mediastinoscopy is negative, surgery will be done                                    
  2\) If mediastinoscopy is positive, non-surgical treatment will be done                   
  b\. If FDG-PET is positive, non-surgical treatment will be done                           
  7                                                                                         All patients were examined by FDG-PET
  a\. If FDG-PET is negative, surgery will be done                                          
  b\. In the presence of distant metastasis, nonsurgical treatment will be done             
  c\. In the presence of metastasis in the mediastinal area, mediastinoscopy will be done   
  1\) If mediastinoscopy is negative, surgery will be done                                  
  2\) If mediastinoscopy is positive, non-surgical treatment will be done                   

The data about technical and clinical performance of PET scan were not available in Iran, because the technology had not yet arrived to the country. Therefore, the main electronic databases including Cochrane Library (Issue 4, 2008) and Medline (Nov 2008) were searched to identify any systematic reviews, economic evaluations and/or health technology assessments published in this area. The quality of retrieved reports was checked using standard CRD (Center for Review and Dissemination) criteria ([@A8559R7]). Those reports that met the quality criteria and were up to date and also had the potential for answering parts or all of the study questions were included. Iranian national databases including IranMedex and SID were searched to identify local and national socio-demographic data and data about the incidence of lung cancer and NSCLC, the staging of disease at the time of diagnosis and other local data required for the model. Retrieved studies and expert opinion were used to estimate the cost of each treatment strategy in Iran. The costs were divided into three categories including capital costs (depreciation costs of buildings and equipment), staff costs and other expenses (including cost of consumables, running and maintenance costs). The costs were estimated in both IR-Rials and US-Dollars with an exchange rate of 10.000 IR Rials per one US Dollar according to the exchange rate in 2008. Sensitivity analysis was used to explore any possible uncertainties in the socio-demographic and costing data. The data about the costs of each strategy were collected according to the local tariffs and expenses in Iran at the time of study. Sensitivity analysis was performed according to the following assumptions. These assumptions were made according to the current situation at the time of the study either from the robust evidence or expert opinions. Assumption A: 3% of patients had distant metastasis, 7% had distant and mediastinal metastasis, 27% had mediastinal metastasis and 63% of patients had local lesions with no metastasis ([@A8559R3]). Assumption B: 4% of patients had distant metastasis, 7% had distant and mediastinal metastasis, 24% had mediastinal metastasis and 65% of patients had local lesions with no metastasis ([@A8559R8]). Assumption C: 20% of patients had distant metastasis, 10% had distant and mediastinal metastasis, 50% had mediastinal metastasis and 20% of patients had local lesions with no metastasis. Assumption D: 20% of patients had distant metastasis, 20% had distant and mediastinal metastasis, 20% had mediastinal metastasis and 10% of patients had local lesions with no metastasis ([Table 2](#tbl3369){ref-type="table"}).

###### Different Assumptions about the Early Detection of NSCLC in Iran

  Grading Cancer   Spread of Cancer      Option A (%)   Option B (%)   Option C (%)   Option D (%)
  ---------------- --------------------- -------------- -------------- -------------- --------------
  N0/1M0           Local                 63             65             20             10
  N0/1M1           Distant Metastasis    3              4              20             20
  N2/3M0           Regional Metastasis   27             24             50             20
  N2/3M1           Both                  7              7              10             20
  Total                                  100            100            100            100

Abbreviations: M, metastasis; N, node

4. Results {#sec10902}
==========

The total costs of setting up a complete PET scan unit were 81600 million Rials (8.2 million US\$). The total costs were 57000 million Rials (5.7 million US\$) when we excluded the building costs and 37400 million Rials (3.7 million US\$) when we excluded the building costs and the costs of the cyclotron unit (Tables [3](#tbl3370){ref-type="table"}, [4](#tbl3371){ref-type="table"}, [5](#tbl3372){ref-type="table"} and [6](#tbl3373){ref-type="table"}). Assuming that a PET scan will perform about 3000 tests a year, the total annual cost of running a PET scan unit including building, equipment, staff and consumable products were 10860 to 13000 million Rials (1.08 to 1.3 million US\$). Excluding the building costs, the total annual cost of running a PET scan were 9430 million to 11000 million Rials (0.9 to 1.1 million US\$). Excluding the building costs and purchasing the FDG-18 from another cyclotron unit, the total annual cost of running a PET scan was 8850 to 10900 million Rials (0.8 to 1.09 million US\$). Considering the above mentioned assumptions, the cost of a PET scan test was 3,000,000 to 4,400,000 Rials (300 to 440 US\$). Assuming a discount rate of zero and a 10% increase in staff salary, the total projected costs of running a complete PET scan unit were about 28 trillion Rials (2800 million US\$) after 20 years (Tables [3](#tbl3370){ref-type="table"}, [4](#tbl3371){ref-type="table"}, [5](#tbl3372){ref-type="table"} and [6](#tbl3373){ref-type="table"}). [Table 7](#tbl3374){ref-type="table"} shows the minimum and maximum local costs of each single intervention that we used to estimate the costs of each strategy.

###### Projected Costs of PET Facility in Iran (Option 1)

  Full Unit in Iran, IRR       Total Capital Costs, IRR   Annual Costs, IRR   Annual lower Costs, IRR   Life, y   Scan/yr   Cost/Scan (High), IRR   Cost/Scan (Low), IRR
  ---------------------------- -------------------------- ------------------- ------------------------- --------- --------- ----------------------- ----------------------
  Scanner                      35,000,000,000             4,486,965,000       4,486,000,000             10        3,000     1,495,655               1,495,333
  Comp Eq                      400,000,000                89,502,400          60,000,000                5         3,000     29,834                  20,000
  Scan Eq                      2,000,000,000              256,398,000         123,000,000               10        3,000     85,466                  41,000
  Building                     9,000,000,000              737,100,000         600,000,000               30        3,000     245,700                 200,000
  Cyclotron                    15,000,000,000             1,234,646,250       1,200,000,000             20        3,000     411,549                 400,000
  Cycl Lab Eq                  5,000,000,000              640,995,000         400,000,000               10        3,000     213,665                 133,333
  Cycl Comp Eq                 200,000,000                44,880,000          30,000,000                5         3,000     14,960                  10,000
  Cycl Build                   15,000,000,000             1,228,500,000       840,000,000               30        3,000     409,500                 280,000
  Total Capital                81,600,000,000             8,718,986,650       7,739,000,000                       3,000     2,906,329               2,579,667
  Staff PET                                               1,410,000,000       965,000,000                         3,000     470,000                 321,667
  Staff Cycl                                              430,000,000         285,000,000                         3,000     143,333                 95,000
  Staff Total                                             1,840,000,000       1,250,000,000                       3,000     613,333                 416,667
  PET Maint                                               200,000,000         150,000,000                         3,000     66,667                  50,000
  Comp Maint                                              20,000,000          15,000,000                          3,000     6,667                   5,000
  Housekeeping                                            30,000,000          20,000,000                          3,000     10,000                  6,667
  Marketing/Training                                      30,000,000          20,000,000                          3,000     10,000                  6,667
  Rod                                                     30,000,000          20,000,000                          3,000     10,000                  6,667
  Power/Building Maint                                    20,000,000          15,000,000                          3,000     6,667                   5,000
  Total PET Maint                                         330,000,000         240,000,000                         3,000     110,000                 80,000
  Cycl Maint                                              150,000,000         100,000,000                         3,000     50,000                  33,333
  Lab Maint                                               40,000,000          30,000,000                          3,000     13,333                  10,000
  Housekeeping                                            40,000,000          40,000,000                          3,000     13,333                  13,333
  Power/Building Maint                                    30,000,000          30,000,000                          3,000     10,000                  10,000
  Total Cycl Maint                                        260,000,000         200,000,000                         3,000     86,667                  66,667
  Scanning Supplies (3000)                                300,000,000         250,000,000                         3,000     100,000                 83,333
  Data Copy                                               40,000,000          40,000,000                          3,000     13,333                  13,333
  Hard Copy and Storage                                   120,000,000         100,000,000                         3,000     40,000                  33,333
  Total PET Variables                                     460,000,000         390,000,000                         3,000     153,333                 130,000
  Lab Supplies                                            500,000,000         350,000,000                         3,000     166,667                 116,667
  Chemicals/Target Materials                              600,000,000         500,000,000                         3,000     200,000                 166,667
  Gases                                                   300,000,000         200,000,000                         3,000     100,000                 66,667
  Total Cycl Variables                                    1,400,000,000       1,050,000,000                       3,000     466,667                 350,000
  Total Costs                                             13,008,986,650      10,869,000,000                      3,000     4,336,329               3,623,000

Abbreviations: Eq, equipment; Cycl, Cyclotron; Maint, maintenance; IRR, Iranian Rial; y, year

###### Projected Costs of PET Facility in Iran (Option 2)

  Full Unit with Free Building Capital Costs   Total Capital Costs, IRR   Annual Costs, IRR   Annual Lower Costs, IRR   Scan/yr   Cost/Scan (High), IRR   Cost/Scan (Low), IRR
  -------------------------------------------- -------------------------- ------------------- ------------------------- --------- ----------------------- ----------------------
  Total Capital                                57,600,000,000             6,753,386,650       6,299,000,000             3,000     2,251,129               2,099,667
  Total Staff                                                             1,840,000,000       1,250,000,000             3,000     613,333                 416,667
  Total PET Maint                                                         330,000,000         240,000,000               3,000     110,000                 80,000
  Total Cycl Maint                                                        260,000,000         200,000,000               3,000     86,667                  66,667
  Total Cycl Variables                                                    1,400,000,000       1,050,000,000             3,000     466,667                 350,000
  Total Costs                                                             11,043,386,650      9,429,000,000             3,000     3,681,129               3,143,000

Abbreviations: Cycl, Cyclotron; Maint, maintenance; IRR, Iranian Rial

###### Projected Costs of PET Facility in Iran (Option 3)

  PET Unit, No Building Capital Cost, No Cyclotron Unit   Total Capital Costs, IRR   Annual Costs, IRR   Annual Lower Costs, IRR   Scan/yr   Cost/Scan (High), IRR   Cost/Scan (Low), IRR
  ------------------------------------------------------- -------------------------- ------------------- ------------------------- --------- ----------------------- ----------------------
  Total Capital                                           37,400,000,000             4,832,865,400       4,669,000,000             3,000     1,610,955               1,556,333
  Total Staff                                                                        1,410,000,000       965,000,000               3,000     470,000                 321,667
  Total PET Maint                                                                    330,000,000         240,000,000               3,000     110,000                 80,000
  Total Cycl Maint                                                                   0                   0                         3,000     0                       0
  Total PET Variables                                                                460,000,000         390,000,000               3,000     153,333                 130,000
  Total Cycl Variables                                                               0                   0                         3,000     0                       0
  Total Cycl Purchase                                                                3,869,482,222       2,590,000,000             3,000     1,289,827               863,333
  Total Costs                                                                        10,902,347,622      8,854,000,000             3,000     3,634,116               2,951,333

Abbreviations: Cycl, Cyclotron; Maint, maintenance IRR, Iranian Rial

###### Projected Costs of a Cyclotron Facility in Iran

  Cyclotron for 6000 Scans, Plus 3000 Delivery   Total Capital Costs, IRR   Annual Costs, IRR   Annual lower Costs, IRR   Scan/yr   Cost/Scan (High), IRR   Cost/Scan (Low), IRR
  ---------------------------------------------- -------------------------- ------------------- ------------------------- --------- ----------------------- ----------------------
  Total Capital                                  35,200,000,000             3,668,964,444       2,470,000,000             6,000     611,494                 411,667
  Staff Cycl Total                                                          600,000,000         400,000,000               6,000     100,000                 66,667
  Total Cycl Maint                                                          370,000,000         260,000,000               6,000     61,667                  43,333
  Total Cycl Variables                                                      2,800,000,000       1,900,000,000             6,000     466,667                 316,667
  Total Cost of Cycl                                                        7,738,964,444       5,180,000,000             6,000     1,289,827               863,333

Abbreviations: Cycl, Cyclotron; Maint, maintenance; IRR, Iranian Rial

###### Different Assumptions About the Costs in Iran

  Costs in the Model, IRR                 Low Costs   Costs, mean   High Costs   Very High Costs
  --------------------------------------- ----------- ------------- ------------ -----------------
  Options for Which the Costs Were Used   Option A    Option B      Option C     Option D
  Surgery, mean                           8,000,000   10,000,000    12,000,000   20,000,000.00
  Chemotherapy                            7,000,000   7,500,000     8,000,000    10,000,000.00
  Radiotherapy                            7,000,000   7,500,000     8,000,000    10,000,000.00
  Mediastinoscopy                         1,500,000   1,750,000     2,000,000    3,500,000.00
  PET                                     4,000,000   5,000,000     6,000,000    7,000,000.00

Abbreviations: IRR, Iranian Rial

Option A - (low cost and low incidence of metastasis): [Table 8](#tbl3375){ref-type="table"} shows that when the CT scan was positive, the third strategy had the lowest cost per QALY followed by the first, fourth, seventh, fifth, sixth and second strategies. In addition, when the CT scan was negative, the first strategy had the lowest cost per QALY, followed by the third, seventh, fifth; fourth, sixth and second strategies. Option D - (high costs and the high incidence of metastasis): when the CT scan results were positive: the third strategy would be associated with the lowest cost per QALY and the fourth; sixth, fifth, second, seventh and the first strategy would be placed in the next steps in an increasing order. When the CT scan results were negative: the third strategy would be associated with the lowest cost per QALY and the fourth; sixth, fifth, seventh, first and second strategy would be placed in the next steps in an increasing order. The incremental cost effectiveness ratio (ICER) for each strategy was calculated for options A and D, presented in Tables [9](#tbl3376){ref-type="table"} and [10](#tbl3377){ref-type="table"}.

###### The Cost Effectiveness of Various Strategies Using PET Scan Technology

                Strategies    The Cost Per QALY for Option A, IRR   The Cost per QALY for Option B, IRR   The cost per QALY for the Option C, IRR   The cost per QALY for Option D, IRR
  ------------- ------------- ------------------------------------- ------------------------------------- ----------------------------------------- -------------------------------------
  1             1\. 1 , CT+   9,355,666                             11,510,392                            11,026,581                                17,344,249
  1\. 2 , CT-   4,873,201     7,007,086                             7,783,681                             12,804,755                                
  2             2\. 1 , CT+   14,756,475                            14,955,508                            14,197,408                                14,214,559
  2\. 2 , CT-   13,990,576    14,083,853                            14,836,450                            14,854,692                                
  3             3\. 1 , CT+   8,456,866                             9,995,084                             9,424,489                                 12,436,273
  3\. 2 , CT-   4,992,172     6,472,773                             6,869,124                             9,976,253                                 
  4             4\. 1 , CT+   10,072,166                            10,544,595                            9,880,870                                 12,507,749
  4\. 2 , CT-   6,865,475     7,523,883                             7,805,994                             10,880,882                                
  5             5\. 1 , CT+   11,063,261                            12,365,090                            11,683,178                                13,895,080
  5\. 2 , CT-   6,617,244     8,002,483                             8,349,699                             11,124,347                                
  6             6\. 1 , CT+   11,519,007                            12,456,886                            11,736,912                                13,868,767
  6\. 2 , CT-   7,028,222     8,152,054                             8,427,113                             11,093,117                                
  7             7\. 1 , CT+   10,449,837                            12,221,175                            11,459,729                                15,260,508
  7\. 2 , CT-   6,227,582     7,929,976                             8,228,064                             11,837,700                                

Abbreviation: QALY, quality adjusted life year; IRR, Iranian Rial

###### The ICER for Option A for Each of the Seven Strategies

  Strategies        Additional Costs Compared to the Cheapest Strategy, IRR   Additional QALY Compared to the Reference (Cheapest) Strategy   ICER
  ----------------- --------------------------------------------------------- --------------------------------------------------------------- ----------------------
  Strategy 3, CT+   -(Cheapest strategy; total cost=606,176,673)              \- (Total QALY=71.68)                                           \-
  Strategy 1, CT+   45,173,038                                                -2.06                                                           Dominated by 3
  Strategy 2, CT+   51,737,840                                                -27.10                                                          Dominated by 3
  Strategy 4, CT+   57,058,552                                                -137.53                                                         Dominated by 3
  Strategy 5, CT+   126,114,721                                               -5.49                                                           Dominated by 3
  Strategy 7, CT+   146,437,292                                               0.34                                                            430,697,918
  Strategy 6, CT+   9,843,856                                                 -5.49                                                           Dominated by 7
  Strategy 1, CT-   -(Cheapest strategy; total cost=922,143,745)              \- (Total QALY=189.23)                                          \-
  Strategy 3, CT-   25,792,563                                                0.65                                                            39,680,866
  Strategy 7, CT-   268,561,423                                               1.97                                                            136,325,595
  Strategy 5, CT-   13,633,874                                                -7.23                                                           Dominated by 7
  Strategy 4, CT-   54,300,961                                                -7.89                                                           Dominated by 7
  Strategy 6, CT-   83,813,918                                                -7.89                                                           Dominated by 7
  Strategy 2, CT-   151,380,548                                               -93.30                                                          Dominated by 7 and 6

Abbreviation: QALY, quality adjusted life year; ICER, incremental cost effectiveness ratio; IRR, Iranian Rial

###### The ICER for Each of the Seven Strategies for Option D

  Strategies        Additional Costs Compared to the Cheapest strategy, IRR   Additional QALY Compared to the Reference Strategy, IRR   ICER
  ----------------- --------------------------------------------------------- --------------------------------------------------------- ------------
  Strategy 2, CT+   -(Cheapest strategy; total cost=971,991,584)              -(Total QALY=68.38)                                       \-
  Strategy 4, CT+   291,191,052                                               32.61                                                     8,929,502
  Strategy 3, CT+   395,177,620                                               41.55                                                     9,510,893
  Strategy 6, CT+   435,937,922                                               33.14                                                     13,154,433
  Strategy 5, CT+   438,609,205                                               33.14                                                     13,235,039
  Strategy 7, CT+   713,684,164                                               42.08                                                     16,960,175
  Strategy 1, CT+   879,992,636                                               38.40                                                     22,916,475
  Strategy 2, CT-   -(Cheapest strategy; total cost=1,028,004,124)            \- (Total QALY=66.2)                                      \-
  Strategy 3, CT-   338,602,822                                               67.79                                                     4,994,879
  Strategy 4, CT-   395,476,409                                               61.62                                                     6,417,988
  Strategy 6, CT-   423,241,750                                               61.62                                                     6,868,578
  Strategy 5, CT-   432,600,379                                               62.10                                                     6,966,190
  Strategy 7, CT-   604,817,207                                               68.73                                                     8,799,901
  Strategy 1, CT-   719,998,578                                               67.31                                                     10,696,755

Abbreviation: QALY, quality adjusted life year; ICER, incremental cost effectiveness ratio; IRR, Iranian Rial

5. Discussion {#sec10903}
=============

We found that strategies 3 (mediastinoscopy alone) and 7 (mediastinoscopy after PET scan) were cost-effective in Iran, especially when the CT scan result was negative. Assuming that a large proportion of Iranian patients might be diagnosed with metastasis in whom surgery cannot be performed, the fourth strategy (PET scan after mediastinoscopy) be more cost effective than the other strategies, especially when the CT scan was negative. Two economic models published in the UK in 2002 and 2007 ([@A8559R3], [@A8559R9]) showed that when diagnosis of NSCLC was confirmed with conventional methods such as biopsy and CT scan, the use of PET-FDG in assessing the degree of malignancy before surgery was cost effective, especially in those patients who had a negative CT scan. The Scottish study indicated that the use of PET scan is effective only if the willingness to pay is higher than 60,000 pounds per QALY ([@A8559R9]). Another study was published in 2003 in Australia showing that use of PET scan leads to an average increase of 0.046 years of patient life (about 17 days) and an average increase of \$189 in cost per each patient. This means that the additional cost per additional QALY gained is about \$ 41.087 ([@A8559R5]). A third study was conducted in 2002 in Scotland that used a decision model with 5 strategies for the evaluation of PET. This study showed that using CT scan without PET scan leads to an increase in life expectancy and reduction in cost. But this approach leads to radiotherapy and unnecessary treatment in 36 percent of the patients. In contrast, when the technology alone and without FDG-PET scans was used, this figure reduced to 4%. In addition, it led to 0.7 increase in the average years and 236 pounds reduction in the cost per patient ([@A8559R5]). Considering the small changes of this technology in the clinical and final outcomes (QALY) of the patients and its small savings costs, the final decision about using or not using this technology in Iran depends on whether the technical performance of the test is considered more important or the clinical final outcomes. If early and more accurate detection of the disease is more important than the final outcomes, then the technology should be considered useful. PET scan seems to be an effective technology and could be diffused in Iran based on a comprehensive technology rationing system at national and regional levels. To increase the efficiency and preventing induced demand, the indication for use of this technology in Iran should be NSCLC. Based on available information, some Iranian medical centers received the license for entering PET scan, but only two of them could enter this technology with attention to this point that PET scan has not been installed completely in these centers yet. The actual costs and clinical findings of PET scan were not available in Iran due to the unavailability of the technology, so the data were estimated based on international evidence. Drummond et al. argued that the clinical data can be used and generalized between the countries ([@A8559R6]). To minimize the possible bias, we used the socio-demographic and costing data according to the local evidence available in Iran.
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